Thyroid C-cell tumors occurred in rats and mice; whether the medicine causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Warnings
Acute pancreatitis; Hypoglycemia with insulin or secretagogues; Acute kidney injury from volume depletion
Interactions
Oral drugs (delayed gastric emptying)
Brand questions use only name pairings verified against the linked product source. Unverified pairings are withheld from these questions; the other study content remains available.
Label date: 20260727 · For learning, not clinical decisions. US label and brand information; always consult the current source.
Source snapshot checked: 2026-10-21. The source document and selected fields were compared. The complete card has not had an independent clinical review.
Mechanism: GLP-1 analogue that selectively binds and activates the GLP-1 receptor; albumin binding gives it a long half-life.
On both cards: Common side effects — Nausea; Diarrhea; Vomiting; Constipation · Warnings — Acute pancreatitis; Hypoglycemia with insulin or secretagogues
Only on the Semaglutide card: Used for — As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; Reduction of major cardiovascular events in adults with type 2 diabetes and established cardiovascular disease; Reduction of sustained eGFR decline, end-stage kidney disease or cardiovascular death in adults with type 2 diabetes and chronic kidney disease · Common side effects — Abdominal pain · Warnings — Diabetic retinopathy complications · Interactions — Insulin secretagogues (e.g. sulfonylureas); Insulin; Oral medications (delayed gastric emptying)
Mechanism: Activates GLP-1 receptors on beta cells, raising cAMP for glucose-dependent insulin release; lowers glucagon, slows gastric emptying.
On both cards: Common side effects — Nausea; Diarrhea; Vomiting; Decreased appetite · Warnings — Acute pancreatitis; Hypoglycemia with insulin or secretagogues
Only on the Dulaglutide card: Used for — Adjunct to diet and exercise for glycemic control in adults and children aged 10 years and older with type 2 diabetes; Reduction of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease or multiple cardiovascular risk factors · Common side effects — Abdominal pain · Warnings — Severe GI reactions / acute kidney injury · Interactions — Oral medications (delayed gastric emptying); Insulin secretagogues / insulin; Warfarin (narrow therapeutic index)
Mechanism: Activates both GIP and GLP-1 receptors; GLP-1 regulates appetite and caloric intake. A fatty diacid prolongs half-life.
On both cards: Common side effects — Nausea; Diarrhea; Vomiting; Constipation · Warnings — Acute pancreatitis
Only on the Tirzepatide card: Used for — With reduced-calorie diet and increased physical activity, long-term weight reduction/maintenance in adults with obesity or overweight plus at least one weight-related comorbidity; With reduced-calorie diet and increased physical activity, moderate-to-severe obstructive sleep apnea in adults with obesity · Common side effects — Abdominal pain · Warnings — Severe GI adverse reactions; Acute gallbladder disease · Interactions — Insulin or sulfonylureas; Oral medications (delayed gastric emptying)
An item counts as shared only when both cards use the same wording. If a card does not list an item, that is not a statement that the effect never occurs.
Boxed warnings on related cards
Semaglutide: Thyroid C-cell tumors occurred in rodents; whether this occurs in humans is unknown. The product is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Dulaglutide: Thyroid C-cell tumors occurred in rats; whether the medicine causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Tirzepatide: Thyroid C-cell tumors occurred in rats; whether the medicine causes these tumors in humans is unknown. It is contraindicated with a personal or family history of medullary thyroid carcinoma or MEN 2.
Capsera